Browse drugs

…llent pathologic responses with only three neoadjuvant doses of cemiplimab. Use of adjuvant radiation was disease-team dependent and in th…

…articipants with resectable HCC received 2 doses of neoadjuvant cemiplimab 350 mg IV every 3 weeks before surgical resection and 8 cycles …

…plimab did not increase cemiplimab’s toxicity.Conclusion Adding peltopepimut-S to cemiplimab did not improve ORR and worsened mOS in the prima…

…ts from a phase 2, multicenter, open-label study of neoadjuvant cemiplimab in patients with high-risk, resectable CSCC ( NCT04315701).Meth…

…ombinations in patients with MM (Cohort A) and CSCC (Cohort B). Pegenzileukin was given at two dose levels (16 µg/kg: Cohort A1 and B1 and 24…

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…sk lesions. Immune checkpoint inhibitors (ICIs) (cemiplimab and pembrolizumab) represent a promising therapeutic option for cases of unresect…

…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…

…esectable CSCC. Neoadjuvant ICIs studies, including cemiplimab, pembrolizumab, and nivolumab±ipilimumab, have reported consistent and strikin…

…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…

…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …